Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel

Lignende værker

• Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
  af: Hayashi, Naoki, et al.
  Udgivet: (2012)
• CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
  af: Adriana Matutino, et al.
  Udgivet: (2018-12-01)
• CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
  af: Matutino, Adriana, et al.
  Udgivet: (2018)
• The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
  af: Chainitikun, Sudpreeda, et al.
  Udgivet: (2020)
• Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
  af: Ngan, Roger K. C.
  Udgivet: (2018)